KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Research & Development (2016 - 2025)

Historic Research & Development for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $358.8 million.

  • Alnylam Pharmaceuticals' Research & Development rose 3243.99% to $358.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 1361.51%. This contributed to the annual value of $1.1 billion for FY2024, which is 1212.82% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Research & Development is $358.8 million, which was up 3243.99% from $323.6 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Research & Development ranged from a high of $358.8 million in Q3 2025 and a low of $169.9 million during Q1 2022
  • Its 5-year average for Research & Development is $250.2 million, with a median of $253.2 million in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Research & Development skyrocketed by 3595.97% in 2021 and then crashed by 861.01% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Research & Development stood at $229.0 million in 2021, then grew by 14.4% to $262.0 million in 2022, then increased by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then increased by 19.54% to $358.8 million in 2025.
  • Its last three reported values are $358.8 million in Q3 2025, $323.6 million for Q2 2025, and $265.1 million during Q1 2025.